Castle Biosciences to Present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum

FRIENDSWOOD, Texas--()--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO, will be presenting at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum on Thursday, November 19th, 2015 at 1:00 p.m. EST in New York.

The live audio webcast and subsequent replay may be accessed by visiting http://wsw.com/webcast/canaccord20/cabi. Please connect to the website at least 15 minutes prior to the live webcast to ensure adequate time for any necessary software download.

About Castle Biosciences

Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow-up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with uveal melanoma (DecisionDx-UM), cutaneous melanoma (DecisionDx-Melanoma) and esophageal cancer (DecisionDx-EC), among others. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ. More information can be found at www.castlebiosciences.com.

DecisionDx-UM, DecisionDx-Melanoma and DecisionDx-EC are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.

Contacts

Investors
Castle Biosciences, Inc.
James L Dunn, Jr., 866-788-9007
CFO
IR@castlebiosciences.com
or
Media
BMC Communications, LLC
Brad Miles, 646-513-3125
Bmiles@bmccommunications.com

Recent Stories

RSS feed for Castle Biosciences, Inc.